Trial Profile
Randomized, Double Blind, Placebo-Controlled, Multicenter Study of a Subcutaneous Formulation of Icatibant for the Treatment of Hereditary Angioedema.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 11 Jun 2021
Price :
$35
*
At a glance
- Drugs Icatibant (Primary)
- Indications Hereditary angioedema
- Focus Therapeutic Use
- Acronyms FAST-1
- Sponsors Shire
- 08 Apr 2009 New trial record.